Abstract
Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer.
Keywords
ImmunotherapyCancer immunotherapyCancerCancer treatmentClinical trialIntensive care medicineBiologyMedicineBioinformaticsInternal medicine
MeSH Terms
HumansImmunotherapyModelsBiologicalNeoplasmsTumor Microenvironment
Affiliated Institutions
Related Publications
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...
Immune Therapy for Cancer
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses ar...
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...
Publication Info
- Year
- 2020
- Type
- review
- Volume
- 52
- Issue
- 1
- Pages
- 17-35
- Citations
- 2118
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2118
OpenAlex
40
Influential
1696
CrossRef
Cite This
Priti S. Hegde,
Daniel S. Chen
(2020).
Top 10 Challenges in Cancer Immunotherapy.
Immunity
, 52
(1)
, 17-35.
https://doi.org/10.1016/j.immuni.2019.12.011
Identifiers
- DOI
- 10.1016/j.immuni.2019.12.011
- PMID
- 31940268